Anti-tumor immunotherapy, radiotherapy, and chemotherapy multimodal combination strategies and interactions in unresectable, locally advanced lung cancer: Clinical practice, mechanism, and biomarker research
- 1Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- 2Department of Radiation Oncology, Peking Union Medical College Hospital; Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- 3Precision Diagnostics Development, Oncology R & D, AstraZeneca, Shanghai, China.
Abstract
Immunotherapy has fundamentally transformed the management of lung cancer. For unresectable, locally advanced non-small cell lung cancer (LA-NSCLC) and limited-stage small-cell lung cancer (LS-SCLC), the current standard of care is platinum-based concurrent chemoradiotherapy (cCRT) followed by consolidation immune-checkpoint blockade, a sequence that significantly prolongs progression-free and overall survival. Attempts to deliver immunotherapy concurrently with cCRT have not improved efficacy in randomized trials and have raised additional safety concerns. Induction chemotherapy plus immunotherapy followed by cCRT is biologically rational and feasible, but definitive benefit awaits phase III confirmation. Optimal sequencing, the most effective immunotherapeutic agents, and the best radiotherapy schedules remain active research priorities. The biological rationale for combining radiotherapy and chemotherapy with immunotherapy rests on their capacity to increase tumor immunogenicity, such as by releasing neoantigens, enhancing major histocompatibility complex-I (MHC-I) expression, and promoting dendritic-cell activation, thereby amplifying subsequent T-cell-mediated cytotoxicity. Yet the same cytotoxic stimuli concurrently elicit lymphodepletion, expand regulatory T cells, and trigger pro- inflammatory cytokine cascades that can blunt antitumor immunity. Consequently, the net therapeutic benefit depends on meticulous optimization of sequencing, fractionation, and dosing to harness immunostimulatory efects while minimizing immunosuppressive sequelae. Circulating tumor DNA, metabolic imaging parameters, and real-time immune-profiling are being integrated into non-invasive biomarker platforms that track response and guide post-concurrent chemoradiotherapy (cCRT) immunotherapy decisions. The next generation of curative-intent therapy will be defined by multidisciplinary, patient-centred treatment plans that combine advanced radiotherapy techniques to reduce toxicity, novel agents such as bispecific antibodies or antibody-drug conjugates, biomarker-driven precision medicine, and proactive adverse-event management.
Related
- Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol
- Muscle strength and muscle mass phenotypes and survival in unresectable hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy-based combination therapy
- Survival outcomes of radiotherapy in elderly patients with unresectable stage III hepatocellular carcinoma: a population-based retrospective cohort study
- Efficacy and toxicities of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for unresectable pancreatic cancer: a systematic review and meta-analysis
- First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial
BibTeX
@article{xu2026antitumor,
title = {{Anti-tumor immunotherapy, radiotherapy, and chemotherapy multimodal combination strategies and interactions in unresectable, locally advanced lung cancer: Clinical practice, mechanism, and biomarker research}},
author = {Yan Xu and Hui Guan and Yuan Wu and Huiyu Huang and Siyuan Yu and Xiaolu Yin and Mengzhao Wang},
journal = {Journal of translational internal medicine},
year = {2026},
month = jun,
doi = {10.1515/jtim-2026-0044},
url = {https://europepmc.org/article/PMC/PMC13726654},
note = {CC BY},
}
RIS
TY - JOUR
TI - Anti-tumor immunotherapy, radiotherapy, and chemotherapy multimodal combination strategies and interactions in unresectable, locally advanced lung cancer: Clinical practice, mechanism, and biomarker research
AU - Yan Xu
AU - Hui Guan
AU - Yuan Wu
AU - Huiyu Huang
AU - Siyuan Yu
AU - Xiaolu Yin
AU - Mengzhao Wang
PY - 2026
DA - 2026/06/13
JO - Journal of translational internal medicine
DO - 10.1515/jtim-2026-0044
UR - https://europepmc.org/article/PMC/PMC13726654
AB - Immunotherapy has fundamentally transformed the management of lung cancer. For unresectable, locally advanced non-small cell lung cancer (LA-NSCLC) and limited-stage small-cell lung cancer (LS-SCLC), the current standard of care is platinum-based concurrent chemoradiotherapy (cCRT) followed by consolidation immune-checkpoint blockade, a sequence that significantly prolongs progression-free and overall survival. Attempts to deliver immunotherapy concurrently with cCRT have not improved efficacy in randomized trials and have raised additional safety concerns. Induction chemotherapy plus immunotherapy followed by cCRT is biologically rational and feasible, but definitive benefit awaits phase III confirmation. Optimal sequencing, the most effective immunotherapeutic agents, and the best radiotherapy schedules remain active research priorities. The biological rationale for combining radiotherapy and chemotherapy with immunotherapy rests on their capacity to increase tumor immunogenicity, such as by releasing neoantigens, enhancing major histocompatibility complex-I (MHC-I) expression, and promoting dendritic-cell activation, thereby amplifying subsequent T-cell-mediated cytotoxicity. Yet the same cytotoxic stimuli concurrently elicit lymphodepletion, expand regulatory T cells, and trigger pro- inflammatory cytokine cascades that can blunt antitumor immunity. Consequently, the net therapeutic benefit depends on meticulous optimization of sequencing, fractionation, and dosing to harness immunostimulatory efects while minimizing immunosuppressive sequelae. Circulating tumor DNA, metabolic imaging parameters, and real-time immune-profiling are being integrated into non-invasive biomarker platforms that track response and guide post-concurrent chemoradiotherapy (cCRT) immunotherapy decisions. The next generation of curative-intent therapy will be defined by multidisciplinary, patient-centred treatment plans that combine advanced radiotherapy techniques to reduce toxicity, novel agents such as bispecific antibodies or antibody-drug conjugates, biomarker-driven precision medicine, and proactive adverse-event management.
SN - 2450-131X
SN - 2224-4018
ER -